Related Experiment Video
Updated: Jun 2, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Sentinel lymph nodes in cutaneous melanoma
1Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, 77030, USA. vprieto@mdanderson.org
Clinics in Laboratory Medicine
|May 10, 2011
Summary
Sentinel lymph node biopsy is a key staging method for cutaneous melanoma, detecting metastatic cells in about 20% of patients. Finding melanoma in these nodes indicates a poorer prognosis.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Sentinel lymph node biopsy (SLN) is the standard for early staging in cutaneous melanoma.
- SLN are the most probable sites for melanoma metastasis.
- SLN allow for more detailed examination than traditional lymphadenectomy.
Purpose of the Study:
- To summarize the current understanding and methods for sentinel lymph node examination in cutaneous melanoma.
- To highlight the diagnostic yield and prognostic implications of positive SLN findings.
Main Methods:
- Review of established protocols for SLN examination.
- Standard histological techniques including hematoxylin and eosin staining.
- Application of immunohistochemistry for enhanced detection of melanoma cells.
Main Results:
- Approximately 20% of cutaneous melanoma patients have detectable melanoma cells in their SLN.
- Detection of melanoma cells in SLN is associated with a significantly impaired prognosis.
- Ongoing research explores the therapeutic implications of removing positive SLN.
Conclusions:
- Sentinel lymph node biopsy is crucial for accurate melanoma staging.
- Positive SLN findings are strong indicators of poor prognosis in cutaneous melanoma patients.
- Further research is needed to establish therapeutic benefits of SLN removal.
